9 NASH Clinical Trials in Tucson, AZ (2026)

Q: How do I join a clinical trial in Tucson?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you.

Recruiting NASH Studies in Tucson

NCT07165028Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associa...

Tucson, AZPHASE34,500 participantsEli Lilly and Company

View Study Details

NCT06632444Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (...

Tucson, AZPHASE31,800 participantsBoehringer Ingelheim

View Study Details

NCT06215716Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The stud...

Tucson, AZPHASE31,650 participantsAkero Therapeutics, Inc

View Study Details

NCT06632457Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated...

Tucson, AZPHASE31,590 participantsBoehringer Ingelheim

View Study Details

NCT06318169Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic stea...

Tucson, AZPHASE31,350 participants89bio, Inc.

View Study Details

NCT06419374Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalco...

Tucson, AZPHASE3762 participants89bio, Inc.

View Study Details

NCT07491458Recruiting

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohe...

Tucson, AZPHASE2180 participantsRivus Pharmaceuticals, Inc.

View Study Details

NCT07288138Recruiting

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reductio...

Tucson, AZPHASE2160 participantsEccogene

View Study Details

NCT05519475Recruiting

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have metabolic dysfunction-associated steatohepatitis (MASH). MAS...

Tucson, AZPHASE2120 participantsRegeneron Pharmaceuticals

View Study Details

About NASH Clinical Trials in Tucson

Nonalcoholic steatohepatitis (NASH/MASH) is a form of fatty liver disease involving liver inflammation and damage caused by fat buildup, not related to alcohol use. It can progress to fibrosis, cirrhosis, and liver failure. Treatment focuses on weight loss, lifestyle changes, and emerging pharmacological therapies.

There are currently 9 nash clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 12,112 participants. Research is being sponsored by Eli Lilly and Company, Boehringer Ingelheim, Akero Therapeutics, Inc and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

NASH Clinical Trials in Tucson — FAQ

Are there nash clinical trials in Tucson?

Yes, there are 9 nash clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What nash treatments are being tested?

The 9 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for nash.

Data updated July 19, 2026 from ClinicalTrials.gov